In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

Users of Ozempic and other drugs are shunning items like energy drinks and salty snacks, research shows. But there are ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

As obesity rates in the United States have reached 41.9 percent among adults, Xevant has released a new e-book, Navigating Obesity Care and GLP-1 Coverage: A Guide for Employers, designed to empower ...

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...